
Beam Therapeutics Inc.
BEAMHealthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97
Financials
Financial Snapshot
Market Cap
$2.73B
Enterprise Value
$2.76B
Revenue (TTM)
$146.6M
Net Income (TTM)
-$107.1M
Cash & Investments
$1.04B
Net Cash
$800.0M
Free Cash Flow (TTM)
-$398.2M
Operating CF (TTM)
-$388.6M
Debt/Equity
0.26
Cash Runway & Burn Rate
Cash on Hand
$1.04B
Quarterly Burn
$97.2M
Monthly Burn
$32.4M
Est. Runway
~10.7 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.9M | $146.4M | $91.8M | $299.7M | $965.6M | $1.08B | $1.19B | $850.7M | $1.25B | $1.04B | |
| Operating Cash Flow | -$2.7M | -$20.3M | -$72.0M | -$95.7M | -$66.3M | $22.5M | -$149.2M | -$347.2M | -$345.1M | -$388.6M | |
| Free Cash Flow | -$3.1M | -$33.4M | -$84.5M | -$112.1M | -$113.1M | -$26.4M | -$182.9M | -$356.2M | -$360.0M | -$398.2M | |
| Capital Expenditure | -$346.0K | -$13.1M | -$12.5M | -$16.4M | -$46.8M | -$49.0M | -$33.7M | -$8.9M | -$14.9M | -$9.6M | |
| Financing Cash Flow | $5.0M | $179.7M | $41.3M | $322.3M | $756.1M | $111.6M | $276.4M | $7.7M | $478.0M | $108.3M |
R&D Spending
R&D (TTM)
$409.0M
R&D Intensity
278.9%
R&D Growth vs Prior
-0.1%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $18.0K | $24.0K | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M | $146.6M | |
| R&D Expense | $5.9M | $33.9M | $54.6M | $103.2M | $387.1M | $311.6M | $437.4M | $367.6M | $409.6M | $409.0M | |
| R&D % of Revenue | — | — | 303438.9% | 429912.5% | 746.6% | 511.5% | 115.8% | 578.7% | 293.1% | 278.9% | |
| SG&A | $2.2M | $11.9M | $20.6M | $29.6M | $57.2M | $87.8M | $116.8M | $111.5M | $113.8M | $130.2M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $18.0K | $24.0K | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M | $146.6M | |
| Cost of Revenue | $0.00 | $33.9M | $54.6M | $103.2M | $232.1M | $311.6M | $0.00 | $367.6M | $22.3M | $0.00 | |
| Gross Profit | $0.00 | -$33.9M | -$54.6M | -$103.2M | -$180.3M | -$250.7M | $377.7M | -$304.0M | $117.4M | $146.6M | |
| R&D | $5.9M | $33.9M | $54.6M | $103.2M | $387.1M | $311.6M | $437.4M | $367.6M | $409.6M | $409.0M | |
| SG&A | $2.2M | $11.9M | $20.6M | $29.6M | $57.2M | $87.8M | $116.8M | $111.5M | $113.8M | $130.2M | |
| Operating Income | -$8.6M | -$45.7M | -$75.2M | -$132.8M | -$392.5M | -$338.5M | -$176.5M | -$415.6M | -$383.7M | -$392.5M | |
| Interest Expense | $0.00 | $0.00 | $187.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $43.7M | $0.00 | |
| Pretax Income | -$8.7M | -$116.7M | -$78.3M | -$194.6M | -$370.6M | -$285.7M | -$131.2M | -$376.7M | -$80.0M | -$107.1M | |
| Net Income | -$8.7M | -$115.3M | -$78.3M | -$194.6M | -$370.6M | -$289.1M | -$132.5M | -$376.7M | -$80.0M | -$107.1M | |
| EPS (Diluted) | -0.62 | -3.28 | -1.53 | -5.49 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -1.04 | |
| EBITDA | -$8.6M | -$45.1M | -$71.7M | -$128.0M | -$230.1M | -$271.5M | -$111.1M | -$354.8M | -$14.0M | -$85.0M | |
| Shares Out. (M) | 12.95 | 35.14 | 51.34 | 46.73 | 64.23 | 70.02 | 77.15 | 82.31 | 98.91 | 104.70 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $146.4M | $37.2M | $162.2M | $560.0M | $232.8M | $435.9M | $282.0M | $294.9M | $213.3M | |
| Short-Term Investments | $0.00 | $0.00 | $54.6M | $137.5M | $405.7M | $845.4M | $754.0M | $568.8M | $950.3M | $830.6M | |
| Total Current Assets | $2.0M | $148.3M | $94.5M | $308.3M | $1.27B | $1.09B | $1.21B | $878.1M | $1.27B | $1.07B | |
| Total Assets | $2.4M | $167.0M | $156.1M | $451.7M | $1.47B | $1.34B | $1.46B | $1.10B | $1.48B | $1.27B | |
| Total Current Liabilities | $6.6M | $25.6M | $29.1M | $102.3M | $213.4M | $223.6M | $205.6M | $182.1M | $96.9M | $82.1M | |
| Long-Term Debt | $0.00 | $0.00 | $4.4M | $5.3M | $3.0M | $0.00 | $0.00 | $0.00 | $139.8M | $100.4M | |
| Total Liabilities | $6.6M | $33.0M | $55.2M | $206.1M | $647.7M | $608.2M | $478.4M | $370.3M | $242.8M | $316.4M | |
| Stockholders' Equity | -$4.2M | $134.0M | $100.9M | $245.6M | $826.7M | $733.5M | $981.3M | $733.5M | $1.24B | $952.7M | |
| Retained Earnings | -$9.5M | -$124.7M | -$203.0M | -$397.6M | -$768.3M | -$1.06B | -$1.19B | -$1.57B | -$1.64B | -$1.99B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M | -$20.3M | -$72.0M | -$95.7M | -$66.3M | $22.5M | -$149.2M | -$347.2M | -$345.1M | -$388.6M | |
| Capital Expenditure | -$346.0K | -$13.1M | -$12.5M | -$16.4M | -$46.8M | -$49.0M | -$33.7M | -$8.9M | -$14.9M | -$9.6M | |
| Free Cash Flow | -$3.1M | -$33.4M | -$84.5M | -$112.1M | -$113.1M | -$26.4M | -$182.9M | -$356.2M | -$360.0M | -$398.2M | |
| Investing Cash Flow | -$346.0K | -$13.4M | -$66.7M | -$100.1M | -$294.1M | -$461.3M | $71.8M | $185.0M | -$121.4M | $225.7M | |
| Financing Cash Flow | $5.0M | $179.7M | $41.3M | $322.3M | $756.1M | $111.6M | $276.4M | $7.7M | $478.0M | $108.3M | |
| Issuance of Stock | $5.0M | $179.7M | $0.00 | $319.5M | $757.4M | $108.3M | $270.2M | $8.2M | $478.0M | $15.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $5.7M | $1.7M | -$2.1M | -$2.3M | -$2.3M | -$485.0K | $0.00 | $94.7M | |
| Stock Based Comp. | $198.0K | $7.0M | $7.0M | $15.4M | $43.6M | $84.3M | $98.6M | $120.7M | $94.2M | -$16.9M | |
| Net Change in Cash | $1.9M | $146.0M | -$97.4M | $126.5M | $395.7M | -$327.2M | $199.1M | -$154.5M | $11.5M | -$54.7M |
Dilution Tracker
Shares outstanding grew 111.6% over 5 years — significant dilution
Shares Outstanding
103M
5-Year Share Growth
+111.6%
Stock Issuance (TTM)
$15.3M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.95 | 35.14 | 51.34 | 46.73 | 64.23 | 70.02 | 77.15 | 82.31 | 98.91 | 104.70 | |
| Change vs Prior % | — | 171.3% | 46.1% | -9.0% | 37.4% | 9.0% | 10.2% | 6.7% | 20.2% | 5.9% | |
| Stock Issuance | $5.0M | $179.7M | $0.00 | $319.5M | $757.4M | $108.3M | $270.2M | $8.2M | $478.0M | $15.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $198.0K | $7.0M | $7.0M | $15.4M | $43.6M | $84.3M | $98.6M | $120.7M | $94.2M | -$16.9M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | -303338.9% | -429812.5% | -347.8% | -411.5% | 100.0% | -478.7% | 84.0% | 100.0% | |
| Operating Margin % | — | — | -417522.2% | -553166.7% | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% | -267.7% | |
| Net Margin % | — | — | -435144.4% | -810800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% | -73.0% | |
| EBITDA Margin % | — | — | -398061.1% | -533437.5% | -443.8% | -445.7% | -29.4% | -558.5% | -10.0% | -57.9% | |
| FCF Margin % | — | — | -469561.1% | -467075.0% | -218.1% | -43.4% | -48.4% | -560.8% | -257.7% | -271.6% | |
| ROE % | 208.7% | -86.0% | -77.6% | -79.2% | -44.8% | -39.4% | -13.5% | -51.4% | -6.5% | -9.7% | |
| ROA % | -363.4% | -69.0% | -50.2% | -43.1% | -25.1% | -21.5% | -9.1% | -34.1% | -5.4% | -8.4% | |
| ROIC % | 272.6% | -32.3% | -56.7% | -37.3% | -30.9% | -30.0% | -13.9% | -44.4% | -27.4% | -32.6% | |
| R&D / Revenue % | — | — | 303438.9% | 429912.5% | 746.6% | 511.5% | 115.8% | 578.7% | 293.1% | 278.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 33.3% | 215916.7% | 17.5% | 520.0% | -83.2% | 120.0% | |
| Gross Profit | 0.0% | 0.0% | -61.2% | -88.9% | -74.8% | -39.0% | 250.7% | -180.5% | 138.6% | |
| Operating Income | 0.0% | -432.1% | -64.3% | -76.7% | -195.6% | 13.8% | 47.9% | -135.5% | 7.7% | |
| Net Income | 0.0% | -1220.3% | 32.0% | -148.4% | -90.5% | 22.0% | 54.2% | -184.3% | 78.8% | |
| EPS (Diluted) | 0.0% | -429.0% | 53.4% | -258.8% | -5.1% | 28.4% | 58.4% | -166.3% | 82.3% | |
| Operating Cash Flow | 0.0% | -649.8% | -254.7% | -33.0% | 30.8% | 134.0% | -762.3% | -132.7% | 0.6% | |
| Free Cash Flow | 0.0% | -994.7% | -152.9% | -32.6% | -0.9% | 76.6% | -592.3% | -94.7% | -1.1% | |
| R&D Expense | 0.0% | 478.1% | 61.2% | 88.9% | 275.2% | -19.5% | 40.4% | -16.0% | 11.4% | |
| SG&A Expense | 0.0% | 438.3% | 73.2% | 44.0% | 93.3% | 53.4% | 33.0% | -4.5% | 2.1% | |
| Total Assets | 0.0% | 6853.0% | -6.5% | 189.4% | 226.4% | -9.0% | 8.8% | -24.4% | 34.2% | |
| Book Value / Share | 0.0% | 1281.1% | -48.5% | 167.2% | 145.0% | -18.6% | 21.4% | -29.9% | 40.5% | |
| Debt | 0.0% | -100.0% | 0.0% | 244.6% | 37.2% | 21.2% | -3.5% | -6.5% | 82.1% | |
| Diluted Shares | 0.0% | 171.3% | 46.1% | -9.0% | 37.4% | 9.0% | 10.2% | 6.7% | 20.2% |
Valuation
P/E (TTM)At Loss
P/S18.60
10Y Low / Med / High5.56 / 44.95 / 158970.84
P/B2.90
10Y Low / Med / High2.14 / 4.92 / 15.54
EV/EBITDAAt Loss
EV/Revenue18.81
10Y Low / Med / High4.86 / 44.07 / 156698.88
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$9.10
Net Current Assets / Share
$7.27
Graham Net-Net
$6.95
Cash / Share
$9.97
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -30.24 | -5.72 | -12.25 | -14.87 | -13.81 | -9.47 | -15.83 | -5.41 | -34.22 | -26.41 | |
| P/S Ratio | 0.00 | 0.00 | 53478.86 | 158970.84 | 98.73 | 44.95 | 5.56 | 32.14 | 19.62 | 18.60 | |
| P/B Ratio | -58.06 | 4.92 | 9.54 | 15.54 | 6.19 | 3.73 | 2.14 | 2.78 | 2.21 | 2.90 | |
| EV/EBITDA | -28.18 | -11.36 | -13.35 | -29.38 | -20.46 | -9.89 | -16.53 | -5.41 | -196.25 | -32.46 | |
| EV/Revenue | 0.00 | 0.00 | 53146.47 | 156698.88 | 90.77 | 44.07 | 4.86 | 30.24 | 19.61 | 18.81 |
Analyst Estimates & Quality
Altman Z-Score
3.74
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $39.1M | $38.8M | $80.6M |
| Net Income | -$454.7M | -$545.9M | -$551.9M |
| EPS | $-4.61 | $-5.10 | $-4.74 |
| # Analysts (EPS) | 11 | 11 | 11 |
Dividends
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Nov 4, 2013 | Dec 2, 2013 | $0.23 | Quarterly |
| Aug 12, 2013 | Sep 3, 2013 | $0.23 | Quarterly |
| May 6, 2013 | Jun 3, 2013 | $0.23 | Quarterly |
| Feb 4, 2013 | Mar 1, 2013 | $0.23 | Quarterly |
| Feb 6, 2012 | Mar 1, 2012 | $0.21 | Quarterly |